While sky high expectations for Eli Lilly’s (NYSE: LLY) tirzepatide have not yet been realized, more positive data add to a growing sense that the future could be as bright as imagined.
Results from the Phase III SURMOUNT-1 trial show strong benefit in using the dual GLP-1/GIP agonist to lessen diabetes risk and maintain significant weight loss.
Over a 176-week period, adults with obesity or overweight and pre-diabetes using weekly tirzepatide injections demonstrated an average weight reduction of 22.9% and significantly reduced their progression to type 2 diabetes, compared to those on placebo.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your account
Try before you buy
Free
7 day trial access
Take a Free Trial
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
Subscribe Now
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
